Prime Medicine presents preclinical data on CGD correction and PASSIGE CAR-T platform at ASGCT

Prime Medicine, Inc.

Prime editing corrected CGD mutation in >90% of CD34+ cells from four donors with no off-target edits detected.
Long-term engraftment >92% editing in vivo supports PM359 advancement as CGD treatment candidate.
PASSIGE platform inserted CD19 CAR (3.5 kb) at TRAC locus in 60% of T cells, with >90% TCR loss.
PASSIGE-generated CAR-T cells showed potent anti-tumor activity in vitro and in vivo.
Multiplex prime editing achieved >90% B2M knockout in primary T cells, enabling allogeneic CAR-T potential.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.